- Đo mỗi 3 ngày đối với BN chức năng thận ổn định
4.Nguyễn Như Hồ, Lư Lan Thanh, Đặng Nguyễn Đoan Trang, Phan Thị Danh, Theo dõi nồng độ Tobramycin trong trị liệu, Tạp chí Y học thành phố, Hội nghị Khoa họ c
TÀI LIỆU THAM KHẢO
1. Abbott Laboratorries Diagnostics Division (2006), Abbott AxSYM® Digoxin II
2. American Society of Health - System Pharmacists (2007), AHFS Drug Information, USA, pp. 3487 - 3493.
3. Burtis C. A., Ashwood E. R. (1999), Tietz Textbook of Clinical Chemistry. W.B. Saunders Company, London, 94-97, 886-888
4. Charles F. Lacy (2007), Drug Information Handbook, Lexicomp
5. Dasgupta A. (2008),Handbook of drug monitoring method, Humana Press. pp 1- 39, 78-79.
6. Destache CJ, Meyer SK, Bittner MJ, Hermann KG (1990), “Impact of clinical pharmacokinetics services on patients treated with aminoglycosides: A cost- benefit analysis”, Ther Drug Monit., 12: 419-426
7. Evans W. E, Schentag J. J, Juoko W. J. (1986), Applied pharmacokinetics: Principles of Therapeutic Drug Monitoring, 2nd, Applied thepeutics Inc, USA, pp. 1105 -1172.
8. Gutshall E.D., Davidson H.E., Davis S.K. (1999), Theophylline, Medication usage evaluation : a screening criteria manual, Insight therapeutics, LLC. 9. Hermsen E. D. (2008), Pharmacokinetic Training Packet for Pharmacist,
Nebraska Medical Center: Clackson and University Hospital.
10. Herry J. B. (2002), Clinical Diagnosis & Management by Laboratory Methods,W.B Sauders Company.
11. Koda-Kimble M.A. Young L.Y., (2000), Applied therapeutics: the clinical use of drugs, 7th, Applied therapeutics, Inc. USA
12. Laurence Bruton et al (2008), Goodman & Gilman’s Manual of Pharmacology and
Therapeutics, Mc Graw Hill.
13. Moffat A. Therapeutic Drug Monitoring(2004), Clarke’s Analysis of Drug and Poisons. Pharmaceutical Press, London, 148 – 153
14. Micromedex Thomson Healthcare (2002), Drug Information for the Health Care Professional, 22nd, The US Pharmacopeial Convention Inc, pp. 689 – 703. 15. Pervaiz M. H. , Michael G. Dickinson, Mohammad Yamani (2006), “Is Digoxin
16. Ried LD, Mc Kenna DA, Horn JR (1989), “Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring”,
Am J Hosp Pharm, 46: 945-951.
17. Schumacher G. E. (1995), Therapeutic Drug Monitoring, Appleton & Lange, ConnecticutTerence J Campell & Peter S MacDonald (2003), “Digoxin In Heart Failure And Cardiac Arrhythmias”, MJA, 179 (98-102).
18. Winter M. E (2000), Basic clinical Pharmacokinetics, Applied Therapeutics, Inc. Vancouver, Washington, pp. 7-102, 147-172. 19. http://www.drugs.com/pro/theophylline.html 20. http://www.rxkinetics.com/theo.html 21. http://www.abbottdiagnostics.com/Science/pdf/learning_immunoassay_02.pd f
Phụ lục 1. Chương trình phần mềm GLOBALRPh.com hỗ trợ việc thực hiện TDM của Aminoglycosid và Vancomycin.
HOME BACK DRUG SEARCH DRUG TABLES DISCLAIMER *HEALTH TOPICS* PROFESSIONAL RESOURCE
Aminoglycoside-Vancomycin Dosing
This document Copyright © 2009 D.McAuley, GlobalRPh Inc. All Rights Reserved.
Patient Name: Location: - PROGRAM HINTS -
Conventional dosing
Select drug: Gentamicin
Select dosing range (if once daily dosing selected):
Gent-tobra: Mild (4 mg/kg)/ Amikacin (10 mg/kg)
Age: Weight: Kg
Male (adsbygoogle = window.adsbygoogle || []).push({});
Scr: Height: Inches
Desired peak: Desired trough: Infusion time: 0.5 Volume of distribution: Select Volume of Distribution (VD) L/kg
Usual range: aminoglycosides: 0.25-0.35 Vanco: 0.65 - 0.9
Calculate Regimen Reset
Hints
Selecting the infusion time
Infusion time (ti)
Sample recommendations
Aminoglycosides: (All doses) 0.5
Vancomycin (0 - 500mg/ 0.5 ) 0.5 501 - 1250 mg 1 1251 -1750 mg 1.5 1751 - 2250 mg 2
Sample recommendations for peak / trough concentrations
Infection Site Peak Trough Peak Trough Peak Trough Abdominal 6-7 <1 25-30 4-6 Cystitis 4-5 <1 20-25 4-6 Endocarditis 4-12 <1.5 25-30 <8 30-40 5-15 Osteomyelitis 6-7 <1 25-30 4-6 30-40 5-20 Pneumonia 8-10 <1.5 25-30 <8 30-40 5-20 Pyelonephritis 6-7 <1 25-30 4-6 25-35 5-10 Sepsis 7-8 <1 25-30 4-6 25-35 5-15 Soft tissue 6-7 <1 20-25 <6 25-35 5-10 Synergy 5-6 <1 20-25 4-6 25-35 5-10 Wound Infections 6-7 <1 25-30 <6 25-35 5-10
Vancomycin - Target trough levels??
M. Goodwin, E. Ashley. Vancomycin: can we teach the mainstay of therapy for gram-positives new tricks? Special to Infectious Disease News. February 2006.